APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cognitive and Memory Enhancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cognitive and Memory Enhancer Drugs Market Analysis and Forecast 2026-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchCognitive and Memory Enhancer Drugs Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Cognitive and Memory Enhancer Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Cognitive and Memory Enhancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cognitive and Memory Enhancer Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Cognitive and Memory Enhancer Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Cognitive and Memory Enhancer Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cognitive and Memory Enhancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cognitive and Memory Enhancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cognitive and Memory Enhancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cognitive and Memory Enhancer Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cognitive and Memory Enhancer Drugs include Takeda Pharmaceutical Company Limited, Takeda, Eisai Co, Johnson & Johnson, Novartis, Pfizer, Ceretropic, Cephalon and AlternaScript, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cognitive and Memory Enhancer Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cognitive and Memory Enhancer Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Cognitive and Memory Enhancer Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cognitive and Memory Enhancer Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cognitive and Memory Enhancer Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cognitive and Memory Enhancer Drugs revenue, projected growth trends, production technology, application and end-user industry.

Cognitive and Memory Enhancer Drugs Segment by Company

Takeda Pharmaceutical Company Limited

Takeda

Eisai Co

Johnson & Johnson

Novartis

Pfizer

Ceretropic

Cephalon

AlternaScript

Allergan

Cognitive and Memory Enhancer Drugs Segment by Type

Namenda

Provigil

Ritalin

Razadyne

Aricept

Exelon

Adderall

Others

Cognitive and Memory Enhancer Drugs Segment by Application

Disease Treatment

Academic Performance

Athletic Performance

Others

Cognitive and Memory Enhancer Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cognitive and Memory Enhancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cognitive and Memory Enhancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cognitive and Memory Enhancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cognitive and Memory Enhancer Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cognitive and Memory Enhancer Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cognitive and Memory Enhancer Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cognitive and Memory Enhancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Namenda Major Player Table 3. Provigil Major Player Table 4. Ritalin Major Player Table 5. Razadyne Major Player Table 6. Aricept Major Player Table 7. Exelon Major Player Table 8. Adderall Major Player Table 9. Others Major Player Table 10. Global Cognitive and Memory Enhancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. Disease Treatment Major Player Table 12. Academic Performance Major Player Table 13. Athletic Performance Major Player Table 14. Others Major Player Table 15. Cognitive and Memory Enhancer Drugs Industry Trends Table 16. Cognitive and Memory Enhancer Drugs Industry Drivers Table 17. Cognitive and Memory Enhancer Drugs Industry Opportunities and Challenges Table 18. Cognitive and Memory Enhancer Drugs Industry Restraints Table 19. Global Cognitive and Memory Enhancer Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 20. Global Cognitive and Memory Enhancer Drugs Market Size by Region (2021-2026) & (US$ Million) Table 21. Global Cognitive and Memory Enhancer Drugs Market Share by Region (2021-2026) Table 22. Global Cognitive and Memory Enhancer Drugs Market Size by Region (2027-2032) & (US$ Million) Table 23. Global Cognitive and Memory Enhancer Drugs Market Share by Region (2027-2032) Table 24. Global Cognitive and Memory Enhancer Drugs Revenue by Players (US$ Million) & (2021-2026) Table 25. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Players (2021-2026) Table 26. Global Cognitive and Memory Enhancer Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 27. Global Cognitive and Memory Enhancer Drugs Key Players Headquarters & Area Served Table 28. Global Cognitive and Memory Enhancer Drugs Players, Product Type & Application Table 29. Global Cognitive and Memory Enhancer Drugs Players Establishment Date Table 30. Global Players Market Concentration Ratio (CR5 and HHI) Table 31. Global Cognitive and Memory Enhancer Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Cognitive and Memory Enhancer Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Type (2021-2026) Table 36. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Type (2027-2032) Table 37. Global Cognitive and Memory Enhancer Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 39. Global Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 40. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Application (2027-2032) Table 42. Takeda Pharmaceutical Company Limited Company Information Table 43. Takeda Pharmaceutical Company Limited Business Overview Table 44. Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Product Portfolio Table 46. Takeda Pharmaceutical Company Limited Recent Development Table 47. Takeda Company Information Table 48. Takeda Business Overview Table 49. Takeda Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Takeda Cognitive and Memory Enhancer Drugs Product Portfolio Table 51. Takeda Recent Development Table 52. Eisai Co Company Information Table 53. Eisai Co Business Overview Table 54. Eisai Co Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Eisai Co Cognitive and Memory Enhancer Drugs Product Portfolio Table 56. Eisai Co Recent Development Table 57. Johnson & Johnson Company Information Table 58. Johnson & Johnson Business Overview Table 59. Johnson & Johnson Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Johnson & Johnson Cognitive and Memory Enhancer Drugs Product Portfolio Table 61. Johnson & Johnson Recent Development Table 62. Novartis Company Information Table 63. Novartis Business Overview Table 64. Novartis Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Novartis Cognitive and Memory Enhancer Drugs Product Portfolio Table 66. Novartis Recent Development Table 67. Pfizer Company Information Table 68. Pfizer Business Overview Table 69. Pfizer Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Pfizer Cognitive and Memory Enhancer Drugs Product Portfolio Table 71. Pfizer Recent Development Table 72. Ceretropic Company Information Table 73. Ceretropic Business Overview Table 74. Ceretropic Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Ceretropic Cognitive and Memory Enhancer Drugs Product Portfolio Table 76. Ceretropic Recent Development Table 77. Cephalon Company Information Table 78. Cephalon Business Overview Table 79. Cephalon Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Cephalon Cognitive and Memory Enhancer Drugs Product Portfolio Table 81. Cephalon Recent Development Table 82. AlternaScript Company Information Table 83. AlternaScript Business Overview Table 84. AlternaScript Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. AlternaScript Cognitive and Memory Enhancer Drugs Product Portfolio Table 86. AlternaScript Recent Development Table 87. Allergan Company Information Table 88. Allergan Business Overview Table 89. Allergan Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Allergan Cognitive and Memory Enhancer Drugs Product Portfolio Table 91. Allergan Recent Development Table 92. North America Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 93. North America Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 94. North America Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 95. North America Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 96. North America Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. North America Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 98. North America Cognitive and Memory Enhancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 99. Europe Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 102. Europe Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 103. Europe Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 104. Europe Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 105. Europe Cognitive and Memory Enhancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 106. China Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. China Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. China Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 109. China Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 111. Asia Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 112. Asia Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 113. Asia Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 114. Asia Cognitive and Memory Enhancer Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 115. Asia Cognitive and Memory Enhancer Drugs Revenue by Region (US$ Million) & (2021-2026) Table 116. Asia Cognitive and Memory Enhancer Drugs Revenue by Region (US$ Million) & (2027-2032) Table 117. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026) & (US$ Million) Table 118. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032) & (US$ Million) Table 119. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026) & (US$ Million) Table 120. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032) & (US$ Million) Table 121. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026) & (US$ Million) Table 123. SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (US$ Million) & (2027-2032) Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Cognitive and Memory Enhancer Drugs Image Figure 2. Global Cognitive and Memory Enhancer Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cognitive and Memory Enhancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Namenda Image Figure 5. Provigil Image Figure 6. Ritalin Image Figure 7. Razadyne Image Figure 8. Aricept Image Figure 9. Exelon Image Figure 10. Adderall Image Figure 11. Others Image Figure 12. Global Cognitive and Memory Enhancer Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Cognitive and Memory Enhancer Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 14. Disease Treatment Image Figure 15. Academic Performance Image Figure 16. Athletic Performance Image Figure 17. Others Image Figure 18. Global Cognitive and Memory Enhancer Drugs Market Size (US$ Million) & (2021-2032) Figure 19. Global Cognitive and Memory Enhancer Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 20. Global Cognitive and Memory Enhancer Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 21. Global Cognitive and Memory Enhancer Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Cognitive and Memory Enhancer Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Cognitive and Memory Enhancer Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Type (2021-2032) Figure 26. Global Cognitive and Memory Enhancer Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 28. Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America Cognitive and Memory Enhancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. North America Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032) Figure 31. North America Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032) Figure 32. North America Cognitive and Memory Enhancer Drugs Revenue Share by Country (2021-2032) Figure 33. United States Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Canada Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Mexico Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Europe Cognitive and Memory Enhancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 37. Europe Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032) Figure 38. Europe Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032) Figure 39. Europe Cognitive and Memory Enhancer Drugs Revenue Share by Country (2021-2032) Figure 40. Germany Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. France Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. U.K. Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Italy Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Spain Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Russia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Netherlands Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. Nordic Countries Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. China Cognitive and Memory Enhancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. China Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032) Figure 50. China Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032) Figure 51. Asia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 52. Asia Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032) Figure 53. Asia Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032) Figure 54. Asia Cognitive and Memory Enhancer Drugs Revenue Share by Region (2021-2032) Figure 55. Japan Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. South Korea Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. India Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Australia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Taiwan Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Southeast Asia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. SAMEA Cognitive and Memory Enhancer Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 62. SAMEA Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032) Figure 63. SAMEA Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Cognitive and Memory Enhancer Drugs Revenue Share by Country (2021-2032) Figure 65. Brazil Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Argentina Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Chile Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Colombia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Peru Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Saudi Arabia Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Israel Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. UAE Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Turkey Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Iran Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Egypt Cognitive and Memory Enhancer Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Namenda
  • Provigil
  • Ritalin
  • Razadyne
  • Aricept
  • Exelon
  • Adderall
  • Others
Applications
  • Disease Treatment
  • Academic Performance
  • Athletic Performance
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • Takeda
  • Eisai Co
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Ceretropic
  • Cephalon
  • AlternaScript
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cognitive and Memory Enhancer Drugs Market by Type
  3. 1.2.1 Global Cognitive and Memory Enhancer Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Namenda
  5. 1.2.3 Provigil
  6. 1.2.4 Ritalin
  7. 1.2.5 Razadyne
  8. 1.2.6 Aricept
  9. 1.2.7 Exelon
  10. 1.2.8 Adderall
  11. 1.2.9 Others
  12. 1.3 Cognitive and Memory Enhancer Drugs Market by Application
  13. 1.3.1 Global Cognitive and Memory Enhancer Drugs Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 Disease Treatment
  15. 1.3.3 Academic Performance
  16. 1.3.4 Athletic Performance
  17. 1.3.5 Others
  18. 1.4 Assumptions and Limitations
  19. 1.5 Study Goals and Objectives
2 Cognitive and Memory Enhancer Drugs Market Dynamics
  1. 2.1 Cognitive and Memory Enhancer Drugs Industry Trends
  2. 2.2 Cognitive and Memory Enhancer Drugs Industry Drivers
  3. 2.3 Cognitive and Memory Enhancer Drugs Industry Opportunities and Challenges
  4. 2.4 Cognitive and Memory Enhancer Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cognitive and Memory Enhancer Drugs Market Perspective (2021-2032)
  2. 3.2 Global Cognitive and Memory Enhancer Drugs Growth Trends by Region
  3. 3.2.1 Global Cognitive and Memory Enhancer Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cognitive and Memory Enhancer Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Cognitive and Memory Enhancer Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cognitive and Memory Enhancer Drugs Revenue by Players
  2. 4.1.1 Global Cognitive and Memory Enhancer Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cognitive and Memory Enhancer Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cognitive and Memory Enhancer Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cognitive and Memory Enhancer Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Cognitive and Memory Enhancer Drugs Players, Product Type & Application
  8. 4.5 Global Cognitive and Memory Enhancer Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cognitive and Memory Enhancer Drugs Market CR5 and HHI
  11. 4.6.3 2025 Cognitive and Memory Enhancer Drugs Tier 1, Tier 2, and Tier 3
5 Cognitive and Memory Enhancer Drugs Market Size by Type
  1. 5.1 Global Cognitive and Memory Enhancer Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Type (2021-2032)
6 Cognitive and Memory Enhancer Drugs Market Size by Application
  1. 6.1 Global Cognitive and Memory Enhancer Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Cognitive and Memory Enhancer Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company Limited
  2. 7.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Limited Cognitive and Memory Enhancer Drugs Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 7.2 Takeda
  8. 7.2.1 Takeda Company Information
  9. 7.2.2 Takeda Business Overview
  10. 7.2.3 Takeda Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Takeda Cognitive and Memory Enhancer Drugs Product Portfolio
  12. 7.2.5 Takeda Recent Developments
  13. 7.3 Eisai Co
  14. 7.3.1 Eisai Co Company Information
  15. 7.3.2 Eisai Co Business Overview
  16. 7.3.3 Eisai Co Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eisai Co Cognitive and Memory Enhancer Drugs Product Portfolio
  18. 7.3.5 Eisai Co Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Cognitive and Memory Enhancer Drugs Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Cognitive and Memory Enhancer Drugs Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Cognitive and Memory Enhancer Drugs Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Ceretropic
  38. 7.7.1 Ceretropic Company Information
  39. 7.7.2 Ceretropic Business Overview
  40. 7.7.3 Ceretropic Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Ceretropic Cognitive and Memory Enhancer Drugs Product Portfolio
  42. 7.7.5 Ceretropic Recent Developments
  43. 7.8 Cephalon
  44. 7.8.1 Cephalon Company Information
  45. 7.8.2 Cephalon Business Overview
  46. 7.8.3 Cephalon Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Cephalon Cognitive and Memory Enhancer Drugs Product Portfolio
  48. 7.8.5 Cephalon Recent Developments
  49. 7.9 AlternaScript
  50. 7.9.1 AlternaScript Company Information
  51. 7.9.2 AlternaScript Business Overview
  52. 7.9.3 AlternaScript Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 AlternaScript Cognitive and Memory Enhancer Drugs Product Portfolio
  54. 7.9.5 AlternaScript Recent Developments
  55. 7.10 Allergan
  56. 7.10.1 Allergan Company Information
  57. 7.10.2 Allergan Business Overview
  58. 7.10.3 Allergan Cognitive and Memory Enhancer Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Allergan Cognitive and Memory Enhancer Drugs Product Portfolio
  60. 7.10.5 Allergan Recent Developments
8 North America
  1. 8.1 North America Cognitive and Memory Enhancer Drugs Revenue (2021-2032)
  2. 8.2 North America Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Cognitive and Memory Enhancer Drugs Revenue by Country
  11. 8.6.1 North America Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Cognitive and Memory Enhancer Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cognitive and Memory Enhancer Drugs Revenue (2021-2032)
  2. 9.2 Europe Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cognitive and Memory Enhancer Drugs Revenue by Country
  11. 9.6.1 Europe Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cognitive and Memory Enhancer Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cognitive and Memory Enhancer Drugs Revenue (2021-2032)
  2. 10.2 China Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032)
  5. 10.3 China Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032)
  9. 10.5 China Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cognitive and Memory Enhancer Drugs Revenue (2021-2032)
  2. 11.2 Asia Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cognitive and Memory Enhancer Drugs Revenue by Country
  11. 11.6.1 Asia Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cognitive and Memory Enhancer Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cognitive and Memory Enhancer Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cognitive and Memory Enhancer Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cognitive and Memory Enhancer Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country
  11. 12.6.1 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cognitive and Memory Enhancer Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst